Saroglitazar found effective in diabetes patients

The novel lipid and glucose lowering drug Saroglitazar showed significant improvements in total cholesterol, high-density cholesterol, hemoglobin A1c and triglyceride levels, without accompanying increases in body weight or serious adverse events in a 9-month study of 787 patients in India with diabetic dyslipidemia when treated with 4 mg daily of saroglitazar.

Glycemic parameters were evaluated at baseline and at 3 months, 6 months, and 9 months.Triglyceride levels were reduced by 43.8% (297.9 ± 122.59 mg/dL to 156.1 ± 50.72 mg/dL; P<0.0001), LDL cholesterol was reduced by 18.5% (132.5 ± 47.90 mg/dL to 100.5 ± 29.87 mg/dL; P<0.0001) and total cholesterol was reduced by 23.1% (239.9 ± 74.66 mg/dL to 176.6 ± 44.56 mg/dL; P<0.0001)

A significant improvement was seen in HDL cholesterol, which rose from 41.0 ± 14.73 mg/ dL at baseline to 44.5 ± 8.31 mg/dLHbA1C dropped from 8.5 ± 1.37% to 7.0 ± 0.78% at 9-month follow-up (P<0.0001), and fasting and postprandial blood sugar were also significantly reduced at 9-month follow-up by 28.1% and 35.2% (P<0.0001) respectively. Saroglitazar has been approved for the treatment of diabetic dyslipidemia in India since September of 2013, and it is the first commercially available dual PPAR alpha and gamma agonist.

The research data was presented at AACE 2015 Annual Meeting at Nashville by Dr. Shashank Joshi, Mumbai.Co-authors included Dr. Jothydev Kesavadev, Dr. Banshi Saboo, Dr. Sudhir Bhandari, Dr. Ashok Jaiswal and Dr. Pankaj Patel.

Read More